MTOR and neoplasm: Based on the concepts of innate and adaptive resistance [4, 5], PD-L1 might be a convergence point for the IFN pathways and the Akt/mTOR pathway, and these pathways may create a vicious cycle in the tumor microenvironment of RCC patients.